Sign in

    Delphine Le Louet

    Senior Financial Analyst at Societe Generale

    Delphine Le Louet is a Senior Financial Analyst at Société Générale, specializing in European healthcare, biotech, and medtech sectors with a particular focus on biotechnology companies. She is responsible for coverage of leading biotech firms across Europe, maintaining a strong track record in delivering in-depth equity research and sector insights, though specific quantitative performance metrics are not publicly available. Delphine has held this position since at least 2014 at Société Générale, following previous tenure as a Senior Analyst at Bernstein covering European SMID healthcare. Her professional background is anchored by deep expertise in healthcare equity research.

    Delphine Le Louet's questions to Inventiva (IVA) leadership

    Delphine Le Louet's questions to Inventiva (IVA) leadership • Q4 2021

    Question

    Delphine Le Louet of Societe Generale asked for confirmation that the R&D spending levels of 2022 would likely continue into 2023 and 2024. She also questioned the potential risk of delays to the NATIVE trial timeline due to the impact of the situation in Eastern Europe, which affects a significant portion of planned patient recruitment, and how the company would manage the demographic balance of the trial population.

    Answer

    CFO Jean Volatier confirmed that projected expenses for 2023 are expected to be in the same range as 2022. Executive Frederic Cren addressed the trial recruitment concerns, stating they do not anticipate the situation will jeopardize the overall timeline. He explained that the company is mitigating the loss of 22 sites in Ukraine and Russia by increasing the total number of global sites to 350 and working with CROs to activate new sites in currently open or new countries to maintain recruitment momentum.

    Ask Fintool Equity Research AI